Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Abbott Laboratories (ABT)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Boston Scientific (BSX) and Abbott Laboratories (ABT) with bullish sentiments.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Boston Scientific (BSX)
Leerink Partners analyst Mike Kratky reiterated a Buy rating on Boston Scientific today and set a price target of $89.00. The company’s shares closed last Monday at $64.40.
According to TipRanks.com, Kratky is ranked #1529 out of 12128 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Boston Scientific with a $103.95 average price target, a 61.9% upside from current levels. In a report issued on March 18, Truist Financial also maintained a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
Abbott Laboratories (ABT)
Bank of America Securities analyst Travis Steed maintained a Buy rating on Abbott Laboratories today. The company’s shares closed last Monday at $103.23, close to its 52-week low of $99.71.
According to TipRanks.com, Steed is a 3-star analyst with an average return of
Currently, the analyst consensus on Abbott Laboratories is a Strong Buy with an average price target of $136.15, a 30.0% upside from current levels. In a report issued on March 24, Wells Fargo also maintained a Buy rating on the stock with a $122.00 price target.
Read More on BSX:
Disclaimer & DisclosureReport an Issue
- Boston Scientific upside scenario unlikely after data, says Wells Fargo
- Netflix initiated, Instacart upgraded: Wall Street’s top analyst calls
- Leerink remains positive on Boston Scientific following CHAMPION-AF readout
- Boston Scientific announces FDA clearance for Asurys Fluid Management System
- Boston Scientific Reports Strong HI-PEITHO Trial Results for EKOS
